Melanoma: all 3,073 studies

Page 7 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.

• Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic CancerCompletedNCT04208958Phase 1/2Results posted
• Family Lifestyles, Actions, and Risk Education Intervention: Version 2CompletedNCT04201223Not applicableResults posted
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced TumorsTerminatedNCT04198818Phase 1/2Results posted
• Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness GenesCompletedNCT04187833Phase 2Results posted
• A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid TumorsTerminatedNCT04157517Phase 1/2Results posted
• Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)TerminatedNCT04152863Phase 2Results posted
• Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in MelanomaActive, not recruitingNCT04139902Phase 2Results posted
• A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant MelanomaCompletedNCT04123470Phase 1/2Results posted
• Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaActive, not recruitingNCT04099251Phase 3Results posted
• Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory MelanomaTerminatedNCT04093323Phase 2Results posted
• Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced MelanomaActive, not recruitingNCT04091750Phase 2Results posted
• Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal MelanomaCompletedNCT04091217Phase 2Results posted
• Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).CompletedNCT04068181Phase 2Results posted
• Symptom Management for YA Cancer SurvivorsCompletedNCT04035447Not applicableResults posted
• A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaActive, not recruitingNCT03999749Phase 2Results posted
• ATL001 in Patients With Metastatic or Recurrent MelanomaTerminatedNCT03997474Phase 1/2Results posted
• PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsTerminatedNCT03993379Phase 2Results posted
• Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid TumorsTerminatedNCT03991741Phase 1Results posted
• High Dose IL-2 in Combination With Anti-PD-1TerminatedNCT03991130Phase 2Results posted
• IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for MelanomaTerminatedNCT03958383Phase 1/2Results posted
• Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in OncologyCompletedNCT03948724Not applicableResults posted
• Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaActive, not recruitingNCT03929029Phase 1Results posted
• Wearable Device Intervention to Improve Sun Behaviors in Melanoma SurvivorsCompletedNCT03927742Not applicableResults posted
• An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain MetastasisTerminatedNCT03911869Phase 2Results posted
• Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain MetastasisTerminatedNCT03903640Phase 2Results posted
• High-Risk Skin Cancers With Atezolizumab Plus NT-I7TerminatedNCT03901573Phase 1/2Results posted
• Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the BrainCompletedNCT03898908Phase 2Results posted
• Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced MalignanciesTerminatedNCT03881488Phase 1Results posted
• Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the BrainCompletedNCT03873818Phase 2Results posted
• Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid TumorsCompletedNCT03864042Phase 1Results posted
• Radiation and Combination Immunotherapy for MelanomaCompletedNCT03850691Phase 2Results posted
• Avadomide (CC-122) in Combination With Nivolumab in Advanced MelanomaCompletedNCT03834623Phase 2Results posted
• Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)CompletedNCT03820986Phase 3Results posted
• Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome InterventionCompletedNCT03817125Phase 1Results posted
• Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersActive, not recruitingNCT03816332Phase 1Results posted
• Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)CompletedNCT03776136Phase 2Results posted
• An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV MelanomaCompletedNCT03765229Phase 2Results posted
• Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic SettingCompletedNCT03743766Phase 2Results posted
• MGC018 With or Without MGA012 in Advanced Solid TumorsTerminatedNCT03729596Phase 1/2Results posted
• Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II ExpressionTerminatedNCT03724968Phase 2Results posted
• Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab TherapyCompletedNCT03719131Phase 2Results posted
• Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)CompletedNCT03715205Phase 4Results posted
• PVSRIPO for Patients With Unresectable MelanomaTerminatedNCT03712358Phase 1Results posted
• A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced MelanomaCompletedNCT03711188Phase 2Results posted
• A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid TumorsCompletedNCT03708328Phase 1Results posted
• Arginase-1 Peptide Vaccine in Patients With Metastatic Solid TumorsCompletedNCT03689192Phase 1Results posted
• A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)CompletedNCT03679767Phase 2Results posted
• Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)CompletedNCT03665597Phase 1Results posted
• pDNA Intralesional Cancer Vaccine for Cutaneous MelanomaCompletedNCT03655756Early Phase 1Results posted
• A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic MelanomaCompletedNCT03635983Phase 3Results posted
• Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous MetastasesCompletedNCT03628417Not applicableResults posted
• A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System MetastasesCompletedNCT03625141Phase 2Results posted
• Denosumab + PD-1 in Subjects With Stage III/ IV MelanomaCompletedNCT03620019Phase 2Results posted
• CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node DiseaseCompletedNCT03618641Phase 2Results posted
• Pembrolizumab and EDP1503 in Advanced MelanomaTerminatedNCT03595683Phase 2Results posted
• 18FDG PET for Early Identification of Tumor Exhaust for Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Bronchopulmonary Carcinoma or MelanomaCompletedNCT03584334Not applicableResults posted
• Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma.CompletedNCT03581188Not applicableResults posted
• Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) MelanomaTerminatedNCT03580382Phase 1/2Results posted
• Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)Active, not recruitingNCT03553836Phase 3Results posted
• SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)TerminatedNCT03552549Phase 2/3Results posted
• Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related OutcomesCompletedNCT03551626Phase 3Results posted
• Skin Self-Examination Education During MammographyCompletedNCT03512457Not applicableResults posted
• Using MC1R Genotype to Impact Melanoma Risk BehaviorCompletedNCT03509467Not applicableResults posted
• APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell CarcinomaCompletedNCT03502330Phase 1Results posted
• Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaCompletedNCT03484923Phase 2Results posted
• Anti-PD-1 Antibody With HD IL-2 in Metastatic MelanomaTerminatedNCT03476174Phase 2Results posted
• UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint BlockadeActive, not recruitingNCT03474497Phase 1/2Results posted
• A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced MelanomaActive, not recruitingNCT03470922Phase 2/3Results posted
• MCS110 With BRAF/MEK Inhibition in Patients With MelanomaCompletedNCT03455764Phase 1/2Results posted
• A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory MelanomaTerminatedNCT03445533Phase 3Results posted
• Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)TerminatedNCT03407170Phase 2Results posted
• Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by SurgeryCompletedNCT03405155Phase 2Results posted
• A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersCompletedNCT03400332Phase 1/2Results posted
• Prostaglandin Inhibition and Immune Checkpoint Blockade in MelanomaCompletedNCT03396952Phase 2Results posted
• Fecal Microbiota Transplant (FMT) in Melanoma PatientsCompletedNCT03341143Phase 2Results posted
• E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)TerminatedNCT03332589Phase 1Results posted
• An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced MelanomaCompletedNCT03329846Phase 3Results posted
• Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable MelanomaTerminatedNCT03325101Phase 1/2Results posted
• A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic MelanomaTerminatedNCT03301636Phase 2Results posted
• Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous CancerTerminatedNCT03300843Phase 2Results posted
• SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast CancerCompletedNCT03294330Phase 3Results posted
• Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV MelanomaCompletedNCT03276832Early Phase 1Results posted
• A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type MelanomaTerminatedNCT03273153Phase 3Results posted
• INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.TerminatedNCT03272464Phase 1Results posted
• Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a MelanomaTerminatedNCT03259425Phase 2Results posted
• Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)TerminatedNCT03241927Phase 2Results posted
• Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorCompletedNCT03239145Phase 1Results posted
• Phase Ib of L-NMMA and PembrolizumabCompletedNCT03236935Phase 1Results posted
• Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2TerminatedNCT03233828Phase 3Results posted
• Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaCompletedNCT03229278Phase 1Results posted
• A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)CompletedNCT03207347Phase 2Results posted
• Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced MelanomaCompletedNCT03200847Phase 1/2Results posted
• Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced MelanomaCompletedNCT03178851Phase 1Results posted
• Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With CancerCompletedNCT03154190Not applicableResults posted
• Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in MelanomaActive, not recruitingNCT03149029Phase 2Results posted
• MAGE-A4ᶜ¹º³²T for Multi-TumorActive, not recruitingNCT03132922Phase 1Results posted
• Skin Health Online for Melanoma: Better Risk AssessmentCompletedNCT03130569Not applicableResults posted
• Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03126110Phase 1/2Results posted
• CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With NivolumabCompletedNCT03123783Phase 1/2Results posted
• LY3022855 With BRAF/MEK Inhibition in Patients With MelanomaCompletedNCT03101254Phase 1/2Results posted

← Melanoma overview